Medicamen Biotech Approves Q1 FY26 Results, Appoints New Directors, and Proposes Dividend Aug 12, 2025
Medicamen Biotech has appointed three new directors: Mr. Ashwani Kumar Sharma as Executive Director, Mr. Sham Goel and Mr. Shaival Saurabh as Non-Executive Independent Directors, each for a five-year term starting August 12, 2025. The company approved unaudited Q1 FY26 results and proposed a final dividend of 10% (Re. 1.00 per equity share) for FY 2024-25, subject to shareholder approval. The 32nd AGM is scheduled for September 26, 2025, via video conference.
Medicamen Biotech Achieves Milestone with First USFDA ANDA Approval Jun 03, 2025
Medicamen Biotech Raises ₹79.41 Crore Through Share and Warrant Allotment Apr 24, 2025
Medicamen Biotech Expands European Presence with New Distribution Agreement Apr 08, 2025
Medicamen Biotech Expands into South African Pharmaceutical Market Mar 10, 2025
More news about Medicamen Biotech
07Mar 25
Medicamen Biotech Expands into South African Pharmaceutical Market with New Partnership
Medicamen Biotech Limited (MBL) has formed a strategic partnership with a major South African conglomerate to register and market its products in South Africa's $4 billion pharmaceutical market. This move follows MBL's recent EU plant approval and aligns with its global expansion strategy. The partnership aims to strengthen MBL's presence in regulated markets and drive future growth.
26Feb 25
Medicamen Biotech Unveils Ambitious ₹1,036 Crore Capital Raise Through Preferential Issue
Medicamen Biotech Limited plans to raise ₹1,036.15 crore through a preferential issue of shares and warrants. The company will issue 13,00,000 equity shares at ₹530 per share to non-promoters, raising ₹689 crore. Additionally, 6,55,000 convertible warrants will be issued at ₹530 each, raising ₹347.15 crore. Post-allotment, promoter Shivalik Rasayan's stake will decrease to 40.67%, while non-promoter Ginnerup Capital APS will increase to 4.69%. The move awaits shareholder and regulatory approvals, with an EGM scheduled for March 26, 2025.
24Feb 25
Medicamen Biotech to Explore Fundraising Options in Upcoming Board Meeting
Medicamen Biotech Ltd. has scheduled a board meeting for February 26 to discuss potential fundraising avenues. The pharmaceutical company's move suggests a possible strategy to strengthen its capital position, which could be used for research and development, expansion plans, working capital, or debt restructuring. This aligns with broader industry trends in the pharmaceutical sector.
21Feb 25
Medicamen Biotech to Explore Fundraising Options in Upcoming Board Meeting
Medicamen Biotech Ltd. has scheduled a board meeting for February 26, 2025, to consider fundraising proposals. The company will explore various options including equity shares issuance, convertible securities, preferential issue, rights issue, and qualified institutional placement. The trading window for the company's securities will be closed from February 21, 2025, until 48 hours after the meeting concludes, in compliance with SEBI regulations.
20Feb 25
Medicamen Biotech Secures 10-Year Manufacturing Deal with US and European Pharma Distributor
Medicamen Biotech Limited has entered into a 10-year manufacturing and supply agreement with a leading pharmaceutical distributor in the US and Europe. The company will use its USFDA-approved Oncology Unit for contract manufacturing. 25% of the total contract amount has been paid upfront. This deal is expected to boost Medicamen Biotech's international presence and manufacturing capabilities.